-
BRAVE: Building Resilience and Values Through E-health
Not Recruiting
More
The purpose of this study is to determine the feasibility and acceptability of tracking
survivors' and their caregivers, stressors, affect, and symptoms using an electronic diary
method, in the time period surrounding their routine check- up with their oncologist.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Webster, 650-725-5577.
Lead Sponsor
Stanford Investigators
View full details
-
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Not Recruiting
More
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating
younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and
not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy
may work better compared to lorlatinib and standard therapy alone in treating younger
patients with neuroblastoma or ganglioneuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Not Recruiting
More
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating
patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway
activation mutations that have spread to other places in the body and have come back or do
not respond to treatment. Selumetinib sulfate may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, .
Stanford Investigators
View full details
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Recruiting
More
The purpose of this study is to determine whether accelerated BEP chemotherapy is more
effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic
germ cell tumours.
Stanford Investigators
View full details
-
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Not Recruiting
More
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib.
In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single
agent and in combination with chemotherapy in patients with relapsed/refractory
neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I
3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6
patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be
initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort
A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Recruiting
More
This partially randomized phase II/III trial studies how well, in combination with surgery,
cisplatin and combination chemotherapy works in treating children and young adults with
hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin,
doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan,
sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving combination chemotherapy may kill more tumor cells than one type of
chemotherapy alone.
Stanford Investigators
View full details
-
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
Not Recruiting
More
This research trial studies saliva, semen, and blood samples to determine effects of
chemotherapy on fertility in osteosarcoma survivors. Study biospecimen samples from
osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes
fertility problems and to learn more about the long term effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, .
Stanford Investigators
View full details
-
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
Recruiting
More
This randomized clinical phase III trial studies how well web-based physical activity
intervention works in improving long term health in children and adolescents with cancer.
Regular physical activity after receiving treatment for cancer may help to maintain a healthy
weight and improve energy levels and overall health.
Stanford Investigators
View full details
-
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
Not Recruiting
More
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIGB), may carry
radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such
as irinotecan and vincristine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving iodine I 131 MIGB
together with irinotecan and vincristine may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of iodine I 131 MIGB
when given together with irinotecan and vincristine in treating young patients with resistant
or relapsed high-risk neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Not Recruiting
More
This pilot phase II trial studies how well rituximab and latent membrane protein
(LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr
virus-positive, cluster of differentiation (CD)20-positive post-transplant
lymphoproliferative disorder. Rituximab is a monoclonal antibody that may interfere with the
ability of cancer cells to grow and spread. LMP-specific T-cells are special immune system
cells trained to recognize proteins found on post-transplant lymphoproliferative disorder
tumor cells if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific
T-cells may work better in treating pediatric organ recipients with post-transplant
lymphoproliferative disorder than rituximab alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Neuroblastoma Precision Trial
Not Recruiting
More
This proposal sets forth the platform for a Precision Medicine clinical trial through the New
Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's
established multi-institutional infrastructure and Translational Genomics Research Institute
GEM sequencing platform for acquisition and gene panel sequencing of relapsed biological
specimens in relapsed/refractory neuroblastoma (rNB) including those obtained from the bone,
bone marrow or soft tissue. Our primary aim is to identify subgroups of rNB patients who have
potentially targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or
immunologic (tumor-associated macrophage infiltration and/or programmed death ligand [PD-L1]
expression) biomarkers in rNB. Additional potential novel biomarkers will also be evaluated
and reported in this cohort of patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sheri Spunt, MD, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Not Recruiting
More
This randomized phase III trial studies how well combination chemotherapy (vincristine
sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan
hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in
treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as
muscle), and has an intermediate chance of coming back after treatment (intermediate risk).
Drugs used work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Combination
chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. It is not yet known whether chemotherapy plus temsirolimus is
more effective than chemotherapy alone in treating patients with intermediate-risk
rhabdomyosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Not Recruiting
More
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+
chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
Stanford is currently not accepting patients for this trial.
For more information, please contact Contact, 650-723-5117.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Not Recruiting
More
This randomized phase III trial is studying different combination chemotherapy regimens and
their side effects and comparing how well they work in treating young patients with newly
diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
may kill more cancer cells. It is not yet known which combination chemotherapy regimen is
more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic
lymphoma. After a common induction therapy, patients were risk assigned and eligible for one
or both post-induction randomizations: Escalating dose Methotrexate versus High Dose
Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation
therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low
Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at
diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction
therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were
all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High
Risk and induction failures. Standard risk patients did not receive nelarabine, High risk
T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures
were assigned to receive Nelarabine.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pediatric Hematology/Oncology, 6504978953.
Stanford Investigators
View full details
-
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Recruiting
More
This phase II trial studies how well reduced doses of radiation therapy to the brain and
spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of
brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using
chemotherapy and radiation therapy have been shown to be effective in treating patients with
WNT-driven medulloblastoma. However, there is a concern about the late side effects of
treatment, such as learning difficulties, lower amounts of hormones, or other problems in
performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill
cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine
sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor
cells and may also reduce the late side effects of treatment.
Stanford Investigators
View full details
-
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide LXS in
treating patients with recurrent, refractory, or persistent neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Judy Hallagan, 6507248811.
Stanford Investigators
View full details
-
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Recruiting
More
This randomized phase III trial studies how well imatinib mesylate works in combination with
two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia
chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to
improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL
when given with strong chemotherapy, but the combination has many side effects. This trial is
testing whether a different chemotherapy regimen may work as well as the stronger one but
have fewer side effects when given with imatinib. The trial is also testing how well the
combination of chemotherapy and imatinib works in another group of patients with a type of
ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL",
and because it is similar to Ph+ ALL, is thought it will respond well to the combination of
agents used to treat Ph+ ALL.
Stanford Investigators
View full details
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Not Recruiting
More
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment
that is directed by genetic testing works in pediatric patients with solid tumors,
non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one
line of standard systemic therapy and/or for which no standard treatment exists that has been
shown to prolong survival. Genetic tests look at the unique genetic material (genes) of
patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit
more from treatment which targets their tumor's particular genetic mutation, and may help
doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sheri L. Spunt, .
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Recruiting
More
This randomized phase III trial studies how well combination chemotherapy works in treating
young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come
back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase
inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving
the drugs in different doses and in different combinations may kill more cancer cells.
Stanford Investigators
View full details
-
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Not Recruiting
More
This phase II trial is studying the side effects of and how well alisertib works in treating
young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 650497881.
Stanford Investigators
View full details
-
Childhood Cancer Survivor Study
Recruiting
More
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer
and its associated therapies. A retrospective cohort study will be conducted through a
multi-institutional collaboration, which will involve the identification and active follow-up
of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age,
between 1970 and 1999 and 10,000 sibling controls. This project will study children and young
adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or
surgery, who are at increased risk of late-occurring adverse health outcomes. A group of
sibling controls will be identified and data collected for comparison purposes.
Stanford Investigators
View full details
-
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Not Recruiting
More
This research study is collecting and storing samples of bone marrow and blood from patients
with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma. Collecting and
storing samples of bone marrow and blood from patients with cancer to study in the laboratory
may help doctors learn more about cancer and help predict the recurrence of cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Not Recruiting
More
This research study is collecting and storing samples of tumor tissue, bone marrow, and blood
from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone
marrow, and blood from patients with cancer to test in the laboratory may help the study of
cancer in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Not Recruiting
More
This phase III trial is studying how well combination chemotherapy works in treating young
patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs
used in chemotherapy work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Giving more than one drug (combination
chemotherapy) may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Dechant, 6507243063.
Stanford Investigators
View full details
-
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Not Recruiting
More
This clinical trial is studying the side effects of combination chemotherapy and to see how
well they work in treating patients with newly diagnosed localized Ewing sarcoma family of
tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Recruiting
More
The primary aim of this randomized phase III trial was to study whether the addition of
maintenance chemotherapy delivered after surgical resection and focal radiation would be
better than surgery and focal radiation alone. The trial also studied if patients who
received induction chemotherapy and then either achieved a complete response or went on to
have a complete resection would also benefit from maintenance chemotherapy. Children ages
1-21 years with newly diagnosed intracranial ependymoma were included. There were 2 arms that
were not randomized. One arm studied patients with Grade II tumors located in the
supratentorial compartment that were completely resected. One arm studied patients with
residual tumor and those patients all received maintenance chemotherapy after focal
radiation. Chemotherapy drugs, such as vincristine sulfate, carboplatin, cyclophosphamide,
etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy
uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a
high dose of radiation directly to the tumor may kill more tumor cells and cause less damage
to normal tissue. Giving chemotherapy in combination with radiation therapy may kill more
tumor cells and allow doctors to save the part of the body where the cancer started.
Stanford Investigators
View full details
-
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Not Recruiting
More
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin,
and sargramostim to see how well it works compared to isotretinoin alone following stem cell
transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as
isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal
antibodies, such as dinutuximab, may block tumor growth in different ways by targeting
certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to
kill cancer cells. It is not yet known if chemotherapy is more effective with or without
dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating
neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Neuroblastoma Biology Study
Recruiting
More
Medical scientists want to find better ways to treat neuroblastoma and to find ways to
prevent the tumor from growing back. To do this, they need more information about the
characteristics of neuroblastoma cells. Therefore, they want to study samples of
neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that
may be related to the growth of neuroblastoma cells. Doctors and other medical scientists
also want to find better ways to detect and measure neuroblastoma to improve the ability to
follow the response of tumor cells to therapy.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This phase III trial studies combination chemotherapy with or without lestaurtinib with to
see how well they work in treating younger patients with newly diagnosed acute lymphoblastic
leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. It is not yet known whether combination chemotherapy is more
effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial is studying dexamethasone to see how well it works compared
to prednisone during induction therapy. This trial is also studying methotrexate and
leucovorin calcium to see how well they work compared to methotrexate alone during
maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia
(ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and
leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop
growing or die. Giving more than one drug may kill more cancer cells. It is not yet known
which combination chemotherapy regimen is more effective in treating acute lymphoblastic
leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Not Recruiting
More
This clinical trial is looking at brain function in young patients receiving methotrexate for
acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain
function may help doctors plan cancer treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
More
This research trial studies biomarkers in tumor tissue samples from patients with newly
diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from
patients with cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer.
Stanford Investigators
View full details
-
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This phase II/III trial is studying the side effects and how well giving dasatinib together
with combination chemotherapy works in treating young patients with newly diagnosed acute
lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle DeChant, 6507243063.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Not Recruiting
More
This randomized phase III trial studies how well combination chemotherapy works in treating
young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come
back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase
inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving
the drugs in different doses and in different combinations may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Not Recruiting
More
This phase I trial is studying the side effects and the best dose of vorinostat when given
together with isotretinoin to see how well it works in treating patients with high-risk
refractory or recurrent neuroblastoma. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Isotretinoin may help vorinostat work
better by making tumor cells more sensitive to the drug. Giving vorinostat together with
isotretinoin may be an effective treatment for neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mario DeSouza, 6507243063.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Not Recruiting
More
This phase III trial is studying combination chemotherapy to see how well it works in
treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Recruiting
More
This phase II trial studies how well dinutuximab works when given with sargramostim in
treating patients with osteosarcoma that has come back after treatment (recurrent).
Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them.
Sargramostim may help the body increase the amount of white blood cells it produces, which
help the body fight off infections. Giving dinutuximab with sargramostim may work better and
kill more cancer cells.
Stanford Investigators
View full details
-
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Not Recruiting
More
This phase III trial studies response-based chemotherapy in treating newly diagnosed acute
myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs
used in chemotherapy work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Response-based chemotherapy separates patients into different risk groups and treats them
according to how they respond to the first course of treatment (Induction I). Response-based
treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in
younger patients with Down syndrome while reducing the side effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Recruiting
More
The study is being done to test the safety of a cancer drug called larotrectinib in children.
The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib
blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat
cancer.
The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe
for children, how the drug is absorbed and changed by their bodies and how well the cancer
responds to the drug. The main purpose of the second study part (Phase 2) is to investigate
how well and how long different cancer types respond to the treatment with larotrectininb.
Stanford Investigators
View full details
-
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Not Recruiting
More
The purpose of this study is to collect and store samples of blood and tumor tissue from
patients with osteosarcoma. Collecting and storing samples of tumor tissue and blood from
patients to test in the laboratory may help the study of cancer in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
Not Recruiting
More
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of
OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from
cisplatin chemotherapy regimens in the treatment of cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized clinical trial is studying giving calaspargase pegol together with
combination chemotherapy to see how well it works compared with giving pegaspargase together
with combination chemotherapy in treating younger patients with newly diagnosed high-risk
acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
more than one drug (combination chemotherapy) may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Not Recruiting
More
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly
diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia
involves high doses of a common class of chemotherapy drugs called anthracyclines, which are
known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may
stop the growth of cancer cells by either killing the cells, by stopping them from dividing,
or by stopping them from spreading. Completely removing or reducing the amount of
anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an
effective treatment for acute promyelocytic leukemia and may reduce some of the long-term
side effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Not Recruiting
More
This phase I/II trial studies the side effects and best dose of liposome-encapsulated
daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and
to see how well they work in treating younger patients with acute myeloid leukemia that has
come back after treatment (relapsed) or is not responding to treatment (is refractory).
Liposome-encapsulated daunorubicin-cytarabine is made up of two chemotherapy drugs,
cytarabine and daunorubicin hydrochloride, and works to stop cancer cell growth by blocking
the cells from dividing. Drugs used in chemotherapy, such as fludarabine phosphate and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim may
increase the production of blood cells and may help the immune system recover from the side
effects of chemotherapy. Giving liposome-encapsulated daunorubicin-cytarabine followed by
fludarabine phosphate, cytarabine, and filgrastim may be a better treatment for patients with
relapsed acute myeloid leukemia and may cause fewer side effects to the heart, a common
effect of other chemotherapy treatments for acute myeloid leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Not Recruiting
More
This phase II trial studies how well denosumab works in treating patients with osteosarcoma
that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy
with monoclonal antibodies, such as denosumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Not Recruiting
More
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide
with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that
has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan
hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and
help kill them or carry tumor-killing substances to them. It is not yet known whether giving
irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more
effective in treating neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Not Recruiting
More
To determine the activity of lenalidomide in the treatment of pediatric subjects with
relapsed/refractory acute myeloid leukemia (AML) (with second or greater relapse or
refractory to at least 2 prior induction attempts) measured by morphological complete
response defined as either a CR or CRi within the first 4 cycles of treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This research trial studies a risk-based classification system for patients with newly
diagnosed acute lymphoblastic leukemia. Gathering health information about patients with
acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best
treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Not Recruiting
More
This randomized phase III trial compares how well combination chemotherapy works when given
with or without bortezomib in treating patients with newly diagnosed T-cell acute
lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help
reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for
cell growth. It may also help chemotherapy work better by making cancer cells more sensitive
to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib
is more effective in treating newly diagnosed T-cell acute lymphoblastic leukemia and T-cell
lymphoblastic lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Not Recruiting
More
This randomized phase III trial studies how well combination chemotherapy with or without
ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to
other parts of the body. Treatment with drugs that block the IGF-1R pathway, such as
ganitumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. It is not yet known whether
adding ganitumab to combination chemotherapy is more effective in treating patients with
newly diagnosed metastatic Ewing sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Not Recruiting
More
This phase II trial studies how well trametinib works in treating patients with juvenile
myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment
(refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Not Recruiting
More
This partially randomized phase III trial studies the side effects of different combinations
of risk-adapted chemotherapy regimens and how well they work in treating younger patients
with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic
lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving more than
one drug (combination chemotherapy), giving the drugs in different doses, and giving the
drugs in different combinations may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Not Recruiting
More
This phase III trial studies how well response and biology-based risk factor-guided therapy
works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may
not need treatment until it progresses. In this case, observation may be sufficient.
Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and
what the best treatment is. Response and biology-based risk factor-guided therapy may be
effective in treating patients with non-high risk neuroblastoma and may help to avoid some of
the risks and side effects related to standard treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-498-7061.
Stanford Investigators
View full details
-
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Not Recruiting
More
This randomized phase II/III trial studies how well pazopanib, when combined with
chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of
patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually
be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs
used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether these therapies can be
safely combined and if they work better when given together in treating patients with
non-rhabdomyosarcoma soft tissue sarcomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial studies how well blinatumomab works compared with standard
combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that
has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab may
allow the body's immune system to attack and destroy some types of leukemia cells. It is not
yet known whether blinatumomab is more effective than standard combination chemotherapy in
treating relapsed B-cell acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Recruiting
More
This phase I/II trial studies the side effects and best dose of nivolumab when given with or
without ipilimumab to see how well they work in treating younger patients with solid tumors
or sarcomas that have come back (recurrent) or do not respond to treatment (refractory).
Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab
in treating patients with recurrent or refractory solid tumors or sarcomas.
Stanford Investigators
View full details
-
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Not Recruiting
More
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib
and combination chemotherapy works in treating patients with newly diagnosed stage II-IV
anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called
brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive
cancer cells in targeted way and delivers vedotin to kill them. Crizotinib and methotrexate
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether brentuximab vedotin and combination chemotherapy is more effective
than crizotinib and combination chemotherapy in treating anaplastic large cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Not Recruiting
More
The study design was an open-label Phase II pediatric clinical study. The purpose of Study
X2203 was to identify any efficacy signal in subjects with the disease subtypes under study,
when treated with pazopanib monotherapy. Furthermore, it was to define the toxicities of
pazopanib in children, as well as examine biological markers, e.g. cytokines and angiogenic
factors, that could help further characterize any response of pazopanib in children.
Pazopanib was administered as monotherapy in tablet and powder suspension formulations at
daily doses of 450 mg/m2/dose or 225 mg/m2/dose, respectively. The first 6 enrolled subjects
receiving oral suspension formulation were assessed for tolerability and extended PK
sampling; and, only if pazopanib was tolerated, subsequent subjects were enrolled at the same
starting dose with the suspension. Dose escalation was not permitted. For the tablet, a
dosing nomogram was used based on the subject's BSA. Dose reduction was dependent upon the
toxicity of pazopanib and disease status of the infants, toddlers, children, adolescents, and
young adults. Subjects could be as young as 1 year-old infants to screen for enrollment.
Subjects were assessed for initial response after 8 weeks of treatment prior to Cycle 3. A
cycle was defined as 28 days of pazopanib treatment with no rest period between cycles.
Treatment was administered continuously once daily. Treatment was to be discontinued if there
was evidence of disease progression, unacceptable treatment-related toxicity, pregnancy.
Histological classification was an important diagnostic inclusion in these subjects with a
wide variety of refractory solid tumors, i.e. 7 different tumor types and each being a
cohort.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, .
Stanford Investigators
View full details
-
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Not Recruiting
More
This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in
treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib
tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving bortezomib and
sorafenib tosylate together with combination chemotherapy may be an effective treatment for
acute myeloid leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds/Hem Onc CRAs, (650) 497-8953.
Stanford Investigators
View full details
-
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Not Recruiting
More
This phase III trial is studying how well combination chemotherapy and radiation therapy work
in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in
chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways
to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses
high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may
kill more tumor cells. It is not yet known which treatment regimen is more effective in
treating low-risk rhabdomyosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Not Recruiting
More
This phase I trial studies the side effects and best dose of lenalidomide when given together
with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma
that does not respond to treatment or that has come back. Drugs used in chemotherapy, such as
lenalidomide and isotretinoin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as dinutuximab, may interfere with the ability of
tumor cells to grow and spread. Giving more than one drug (combination chemotherapy) together
with dinutuximab therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
Not Recruiting
More
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG)
and compare their effects on tumor response and associated side effects, to determine if one
therapy is better than the other for people diagnosed with relapsed or persistent
neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
More
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when
given together with gemcitabine hydrochloride and to see how well they work in treating
younger patients with Hodgkin lymphoma that has returned or does not respond to treatment.
Monoclonal antibodies, such as brentuximab vedotin, may find cancer cells and help kill them.
Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer
cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Not Recruiting
More
This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to
characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor
activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses
(approximately 2 years) in children and young adults with B7-H3-expressing relapsed or
refractory malignant solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Zoledronic acid may stop the growth of tumor
cells in bone. Giving bevacizumab together with cyclophosphamide and zoledronic acid may kill
more tumor cells.
PURPOSE: This phase I trial is studying the side effects of giving bevacizumab together with
cyclophosphamide and zoledronic acid in treating patients with recurrent or refractory
high-risk neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mario DeSouza, 6507243063.
Stanford Investigators
View full details
-
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of intravenous
fenretinide in treating young patients with recurrent or resistant neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mario Desouza, 6507243063.
Stanford Investigators
View full details
-
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Not Recruiting
More
This phase II trial studies how well chemotherapy followed by radiation therapy work in
treating younger patients with newly diagnosed central nervous system germ cell tumors that
have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as
chemotherapy, such as carboplatin, etoposide, and ifosfamide, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Radiation therapy uses high-energy x rays to kill tumor cells.
Giving chemotherapy followed by radiation therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial is studying different combination chemotherapy regimens and
comparing how well they work in treating patients with newly diagnosed acute lymphoblastic
leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact LPCH New Patient Coordinator, 6507251072.
Stanford Investigators
View full details
-
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Not Recruiting
More
This phase III trial is studying observation to see how well a risk based treatment strategy
works in patients with soft tissue sarcoma. In the study, patients are assigned to receive
surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes,
after surgery, the tumor may not need additional treatment until it progresses. In this case,
observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells.
Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving these treatments
after surgery may kill any tumor cells that remain after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Not Recruiting
More
Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children
and adolescent with primary mediastinal large B cell lymphoma in terms of event free
survival.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Not Recruiting
More
This randomized phase II/III trial is studying vorinostat, temozolomide, or bevacizumab to
see how well they work compared with each other when given together with radiation therapy
followed by bevacizumab and temozolomide in treating young patients with newly diagnosed
high-grade glioma. Vorinostat may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses
high-energy x-rays to kill tumor cells. It is not yet known whether giving vorinostat is more
effective then temozolomide or bevacizumab when given together with radiation therapy in
treating glioma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Recruiting
More
This research trial studies neuropsychological (learning, remembering or thinking) and
behavioral outcomes in children and adolescents with cancer by collecting information over
time from a series of tests.
Stanford Investigators
View full details
-
Study of Kidney Tumors in Younger Patients
Recruiting
More
This research trial studies kidney tumors in younger patients. Collecting and storing samples
of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may
help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify
biomarkers related to cancer.
Stanford Investigators
View full details
-
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Recruiting
More
This clinical trial studies cancer survivors to identify those who are at increased risk of
developing late-occurring complications after undergoing treatment for childhood cancer. A
patient's genes may affect the risk of developing complications, such as congestive heart
failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer
treatment. Genetic studies may help doctors identify survivors of childhood cancer who are
more likely to develop late complications.
Stanford Investigators
View full details
-
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
More
This clinical trial keeps track of and collects follow-up information from patients who are
currently enrolled on or have participated in a Children's Oncology Group study. Developing a
way to keep track of patients who have participated in Children's Oncology Group studies may
allow doctors learn more about the long-term effects of cancer treatment and help them reduce
problems related to treatment and improve patient quality of life.
Stanford Investigators
View full details
-
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Not Recruiting
More
The purpose of this study is to collect and store tumor tissue, blood, and bone marrow
samples from patients with soft tissue sarcoma that will be tested in the laboratory.
Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test
in the laboratory may help the study of cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Not Recruiting
More
This phase III trial studies the side effects and how well risk-based therapy works in
treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs
(cancer fighting medicines), and when necessary, liver transplant, are the main current
treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best
treatment. Treating patients according to the risk group they are in may help get rid of the
cancer, keep it from coming back, and decrease the side effects of chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Not Recruiting
More
This pilot, phase II trial studies the side effects of giving bortezomib together with
combination chemotherapy and to see how well it works in treating young patients with
relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving bortezomib together with combination
chemotherapy may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
